At Epigenica, we build innovative products for epigenetic analysis that foster scientific breakthroughs to advance human health.
Current commercial epigenomics technologies are limited by their ability to profile one or a few marks and samples at a time, at low throughput and high cost. Today, researchers can screen for either DNA methylation (DNAm) or histone post-translational modifications (HPTMs) – but not both simultaneously. Experiments also require many cells to generate accurate information. Considerable input material is needed to undertake comprehensive, epigenetic screens across multiple samples and multiple epigenetic markers, because it’s difficult to make quantitative comparisons across studies or samples, the utility of epigenetic research is limited.
This website uses cookies. By continuing to use this site, you accept our use of cookies.